BioCentury
ARTICLE | Distillery Therapeutics

Cardiovascular

May 9, 2018 3:16 PM UTC

Cell culture and rat studies suggest nanoparticles loaded with cerivastatin could help treat pulmonary arterial hypertension (PAH) without the cytotoxicity of free cerivastatin. In a rat model of PAH, intratracheal administration of liposomes loaded with cerivastatin, a HMG-CoA reductase inhibitor, decreased pulmonary arterial pressure and right ventricular wall thickness compared with intratracheal free cerivastatin or vehicle. Also in the rat model, intratracheal administration of the cerivastatin-loaded liposomes decreased liver and serum levels of a cytotoxic cerivastatin metabolite compared with IV delivery of free cerivastatin. Next steps could include testing the cerivastatin-loaded liposomes in additional toxicity assays...

BCIQ Company Profiles

Indiana University

BCIQ Target Profiles

HMG-CoA reductase